Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 15/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | FLT4 | P35916 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22925496 | 0.86 | TRPV1 (0.47) | CHEK1FLT1FLT4KDRIMPDH2 | |
| SCHEMBL24636881 | 0.86 | CHEK1 (0.40) | CHEK1SCN10AFLT1FLT4KDR | |
| SCHEMBL29620967 | 0.86 | TRPV1 (0.47) | CHEK1FLT1FLT4KDRIMPDH2 | |
| SCHEMBL29620873 | 0.86 | CHEK1 (0.40) | CHEK1SCN10AFLT1FLT4KDR | |
| SCHEMBL24637089 | 0.86 | NPSR1 (0.38) | KDM4ENPSR1KIF11FLT1FLT4 | |
| SCHEMBL22925742 | 0.86 | CHEK1 (0.40) | CHEK1FLT1FLT4KDRIMPDH2 | |
| SCHEMBL29620891 | 0.86 | CHEK1 (0.40) | CHEK1FLT1FLT4KDRIMPDH2 | |
| SCHEMBL28733613 | 0.85 | MEN1 (0.40) | CHEK1FLT1FLT4KDRIMPDH2 | |
| SCHEMBL29620907 | 0.85 | MEN1 (0.40) | CHEK1FLT1FLT4KDRIMPDH2 | |
| SCHEMBL22925935 | 0.84 | CHEK1 (0.38) | CHEK1KDM4ENPSR1FLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114450281-B | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20220274970-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-09-01 | — | — | US | disclosed |
| EP-4003986-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-06-01 | — | — | EP | disclosed |
| CN-114450281-A | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2021012018-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | SERPINB1, MMP1, SSB | CHEK1 1509/4885KDM4E 1551/4885NPSR1 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.